Iglesias T, Cabrera-Poch N, Mitchell M P, Naven T J, Rozengurt E, Schiavo G
Molecular Neuropathobiology, Cell Biology, Computational Genome Analysis, and Protein Sequencing Laboratories, Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom.
J Biol Chem. 2000 Dec 22;275(51):40048-56. doi: 10.1074/jbc.M005261200.
Protein kinase D (PKD) is a serine/threonine kinase regulated by diacylglycerol signaling pathways with unique domain composition and enzymatic properties, still awaiting identification of its specific substrate(s). Here we have isolated, cloned, and characterized a novel protein from PC12 cells, termed Kidins220 (kinase D-interacting substrate of 220 kDa), as the first identified PKD physiological substrate. Kidins220 contains 11 ankyrin repeats and four transmembrane domains within the N-terminal region. We have shown that Kidins220 is an integral membrane protein selectively expressed in brain and neuroendocrine cells, where it concentrates at the tip of neurites. In PC12 cells, PKD co-immunoprecipitates and phosphorylates endogenous Kidins220. This phosphorylation is increased after stimulating PKD activity in vivo by phorbol-12, 13-dibutyrate treatment. A constitutively active PKD mutant (PKD-S744E/S748E) phosphorylates recombinant Kindins220-VSVG in vitro in the absence of phorbol-12,13-dibutyrate. Conversely, Kidins220-VSVG phosphorylation is abolished when a dominant negative mutant of PKD (PKD-D733A) is used. Moreover, a peptide within the Kidins220 sequence, containing serine 919 in a consensus motif for PKD-specific phosphorylation, behaved as the best peptide substrate to date. Substitution of serine 919 to alanine abrogated peptide phosphorylation. Furthermore, by generating an antibody recognizing Kidins220 phosphorylated on serine 919, we show that phorbol ester treatment causes the specific phosphorylation of this residue in PC12 cells in vivo. Our results provide the first physiological substrate for PKD and indicate that Kidins220 is phosphorylated by PKD at serine 919 in vivo.
蛋白激酶D(PKD)是一种丝氨酸/苏氨酸激酶,受二酰基甘油信号通路调控,具有独特的结构域组成和酶活性,其特定底物仍有待确定。在此,我们从PC12细胞中分离、克隆并鉴定了一种新型蛋白质,命名为Kidins220(220 kDa的激酶D相互作用底物),它是首个被鉴定出的PKD生理底物。Kidins220在N端区域含有11个锚蛋白重复序列和4个跨膜结构域。我们发现Kidins220是一种整合膜蛋白,在脑和神经内分泌细胞中选择性表达,并集中在神经突的末端。在PC12细胞中,PKD与内源性Kidins220进行共免疫沉淀并使其磷酸化。在用佛波醇-12,13-二丁酸酯处理体内PKD活性后,这种磷酸化作用增强。一种组成型活性PKD突变体(PKD-S744E/S748E)在体外无佛波醇-12,13-二丁酸酯存在的情况下可使重组Kindins220-VSVG磷酸化。相反,当使用PKD的显性负性突变体(PKD-D733A)时,Kidins220-VSVG的磷酸化作用被消除。此外,Kidins220序列中的一个肽段,其丝氨酸919位于PKD特异性磷酸化的共有基序中,是迄今为止表现最佳的肽底物。将丝氨酸919替换为丙氨酸可消除肽的磷酸化。此外,通过制备一种识别丝氨酸919磷酸化的Kidins220的抗体,我们发现在体内佛波醇酯处理可导致PC12细胞中该残基的特异性磷酸化。我们的结果为PKD提供了首个生理底物,并表明在体内Kidins220在丝氨酸919处被PKD磷酸化。